Log in to search using one of your social media accounts:

 

Morphosys jumps pre-market as FDA approves antibody drug

FRANKFURT (Reuters) - Shares in Morphosys jumped 11 percent in pre-market trade on Friday after a licensee won U.S. approval for psoriasis drug guselkumab, bringing the German biotech group a step closer to launching its first antibody drug onto the market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Psoriasis patients experience chronic systemic skin inflammation and develop cardiovascular comorbidities that shorten their lifespan. Whether cardiovascular disease is improved by treatment with current biologics that target disease-specific pathways is unclear. KC-Tie2 mice develop psoriasiform skin inflammation with increases in IL-23 and IL-17A and proinflammatory monocytosis and neutrophilia that precedes development of carotid artery thrombus formation. To examine whether targeted blockade of IL-23 or IL-17A in KC-Tie2 psoriasis mice improves cardiovascular outcomes, mice were treated systemically for 6 weeks with an...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research
AbstractGP2015 is the second biosimilar of the reference p75 TNF receptor-Fc fusion protein etanercept. It is approved for use in all indications for which reference etanercept is approved, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis. GP2015 has similar physiochemical and pharmacodynamic properties to those of reference etanercept, and the pharmacokinetic biosimilarity of the agents has been shown in healthy volunteers. GP2015 demonstrated clinical efficacy equivalent to...
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
Targeting Ripk1 could be an effective treatment for skin conditions such as eczema and psoriasis, a study finds.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Letters to the Editor Source Type: research
Linked Article: Gisondi. Br J Dermatol 2017; 177:837–844
Source: British Journal of Dermatology - Category: Dermatology Authors: Tags: Editorial Source Type: research
Linked Article: Simpson et al. Br J Dermatol 2017; 177:742–750.
Source: British Journal of Dermatology - Category: Dermatology Authors: Tags: Commentary Source Type: research
Linked Article: Nelson et al. Br J Dermatol 2017; 177:758–770.
Source: British Journal of Dermatology - Category: Dermatology Authors: Tags: Commentary Source Type: research
Abhishek De, Tanumay Raychaudhury, Murlidhar Rajagopalan, Aarti Sarda, Nidhi SharmaIndian Journal of Dermatology 2017 62(5):533-535
Source: Indian Journal of Dermatology - Category: Dermatology Authors: Source Type: research
Kenit P Ardeshna, Shylaja Someshwar, Shaurya Rohatgi, Hemangi R JerajaniIndian Journal of Dermatology 2017 62(5):537-538
Source: Indian Journal of Dermatology - Category: Dermatology Authors: Source Type: research
Shekhar Neema, Anupam Das, Nalin Shankar SinghIndian Journal of Dermatology 2017 62(5):542-544
Source: Indian Journal of Dermatology - Category: Dermatology Authors: Source Type: research
More News: Biotechnology | Germany Health | Health | Psoriasis